GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Black Diamond
Black Diamond is a biotech company developing targeted drugs for the treatment of cancers caused by specific genetic mutations. Its stock price is a venture bet on the precision of its scientific platform. The stock chart is driven by news from clinical trials.
Share prices of companies in the market segment - Oncology targeted therapy
Black Diamond Therapeutics is an oncology company developing targeted therapies for patients with genetic mutations that are resistant to standard therapy. We've categorized it as "Targeted Oncology." The chart below shows how the market views personalized medicine approaches.
Broad Market Index - GURU.Markets
Black Diamond Therapeutics is an oncology company developing targeted therapies for patients with genetic mutations that are resistant to standard therapy. As a component of the GURU.Markets index, it represents the personalized medicine sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
BDTX - Daily change in the company's share price Black Diamond
Black Diamond, an oncology company, has a volatility measured by change_co. It reflects extreme sensitivity to clinical trial results. This metric is a critical element in the formulas on System.GURU.Markets for analyzing high-risk biotech companies, where every event represents a binary outcome.
Daily change in the price of a set of shares in a market segment - Oncology targeted therapy
Black Diamond Therapeutics, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with BDTX's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Black Diamond Therapeutics is a biotech company developing targeted therapies for cancers caused by specific mutations. Its stock is a bet on scientific precision and breakthroughs. Its high data-driven volatility contributes to overall market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Black Diamond
Black Diamond Therapeutics' year-to-date performance is a story about developing targeted drugs for the treatment of cancers caused by rare mutations. Its 12-month market cap depends entirely on progress in early clinical trials, where it must prove that its approach, based on genomic data analysis, can lead to the creation of effective drugs.
Annual dynamics of market capitalization of the market segment - Oncology targeted therapy
Black Diamond Therapeutics, Inc. is a biotech company developing precision-targeted drugs for the treatment of cancers caused by specific mutations. Its stock performance is entirely dependent on clinical trial results. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Black Diamond is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Black Diamond
The value of Black Diamond, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but news about the progress of clinical trials of its targeted oncology drugs, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Oncology targeted therapy
Black Diamond Therapeutics is an oncology company developing targeted therapies for patients with genetic mutations previously considered difficult to treat. The biotech sector's dynamics reflect investors' faith in scientific breakthroughs. Black Diamond's story is an attempt to create treatments for specific patient groups in this highly competitive environment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Black Diamond Therapeutics, Inc. is a biopharmaceutical company developing targeted oncology drugs for patients with genetically determined cancers. The company's future depends on the success of its clinical trials. The broader market chart serves as just a backdrop to demonstrate how its scientific approach and progress in trials have driven its stock price movement independently.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Black Diamond
Black Diamond Therapeutics is a clinical-stage oncology company developing targeted therapies for genetically specific cancers. Its weekly stock price, like that of other biotech companies, is entirely dependent on the publication of clinical trial data.
Weekly dynamics of market capitalization of the market segment - Oncology targeted therapy
Black Diamond Therapeutics develops targeted therapies for cancers caused by specific genetic mutations. This is a cutting-edge, yet risky, field. The chart clearly demonstrates how the company's shares operate in their own information space, reacting to research data rather than general market trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Black Diamond is an oncology company working in the promising field of precision medicine. Its shares are a pure bet on a scientific breakthrough. The chart clearly shows their extreme volatility and complete dependence on news about clinical trials.
Market capitalization of the company, segment and market as a whole
BDTX - Market capitalization of the company Black Diamond
Black Diamond Therapeutics' market capitalization reflects its focus on developing targeted therapies for cancers caused by specific genetic mutations. As a clinical-stage company, its valuation is highly volatile and dependent on the success of its research. It's a high-risk bet on cutting-edge oncology.
BDTX - Share of the company's market capitalization Black Diamond within the market segment - Oncology targeted therapy
Black Diamond Therapeutics is a clinical-stage biotech company developing targeted therapies for cancers caused by specific genetic mutations. Its market share reflects the potential of its platform. Its growth rate is a bet that its precision medicine approach will lead to effective treatments.
Market capitalization of the market segment - Oncology targeted therapy
The chart below shows the overall value of the biotech sector. Black Diamond Therapeutics is a precision oncology company. Its unique approach involves creating drugs for mutations previously considered "inaccessible." The potential of this market is enormous, and Black Diamond is at the forefront of this complex scientific challenge.
Market capitalization of all companies included in a broad market index - GURU.Markets
Black Diamond is a biotech company developing targeted drugs for the treatment of cancer caused by specific genetic mutations. Its market capitalization is a bet on precision oncology. The chart below shows the economic weight of companies developing "smart" drugs.
Book value capitalization of the company, segment and market as a whole
BDTX - Book value capitalization of the company Black Diamond
Black Diamond's book value is derived from its R&D platform for developing targeted cancer therapies targeting genetic mutations and its capital for clinical trials. The chart tells the story of a biotech company investing in its innovative approach to precision oncology, building the intangible foundation for future drugs.
BDTX - Share of the company's book capitalization Black Diamond within the market segment - Oncology targeted therapy
Black Diamond Therapeutics develops targeted therapies for cancer treatment. The chart shows its share of actual R&D assets. These are its laboratories, where, using its proprietary MAP platform, new drugs are discovered against genetic mutations previously considered untreatable.
Market segment balance sheet capitalization - Oncology targeted therapy
Black Diamond is a biotech company whose value is locked into its scientific platform. Its business is capital-light. The chart below reflects the capital intensity of the pharmaceutical sector, which underscores its R&D-focused model.
Book value of all companies included in the broad market index - GURU.Markets
Black Diamond Therapeutics develops targeted therapies for cancers caused by specific genetic mutations. The company's assets include its scientific platform. A modest stake in BCap_All represents a material resource aimed at creating "smart" drugs that act with high precision.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Black Diamond
Black Diamond is an oncology biotech company. Its market capitalization is a premium to its cash flow, reflecting its scientific platform for developing targeted therapies for genetically specific cancers.
Market to book capitalization ratio in a market segment - Oncology targeted therapy
Black Diamond Therapeutics is a biotech company developing targeted cancer therapies. Its value is based almost entirely on its scientific platform. The chart shows the significant premium to book value that investors are paying for the potential of its precision oncology drugs.
Market to book capitalization ratio for the market as a whole
Black Diamond Therapeutics is a biotech company developing targeted therapies for cancers caused by specific mutations. Its entire value lies in its scientific platform. This chart clearly demonstrates how market valuation in biotech can be detached from balance sheet valuation, reflecting faith in a scientific breakthrough.
Debts of the company, segment and market as a whole
BDTX - Company debts Black Diamond
Black Diamond Therapeutics, an oncology company developing targeted therapies, is raising capital to fund its research platform. The debt leverage reflects the cost of identifying new genetic drivers of cancer and conducting preclinical and early clinical trials for its innovative drug candidates.
Market segment debts - Oncology targeted therapy
Black Diamond Therapeutics is a biotech company developing targeted therapies for cancers caused by specific genetic mutations. This approach requires extensive research and significant funding. This chart shows whether the company is pursuing the standard biotech equity financing model.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Black Diamond
Black Diamond Therapeutics is an oncology company developing targeted therapies. Its future depends on the success of long-term, expensive clinical trials. This chart shows how much the company finances its R&D with debt. This information is critical for assessing its financial runway and the risks involved before drug approval.
Market segment debt to market segment book capitalization - Oncology targeted therapy
Black Diamond Therapeutics is a biotech company developing targeted therapies for cancers caused by specific genetic mutations. The chart shows debt trends in the sector. It helps assess how the company funds its research and how its precision medicine-based financial model compares to other oncology startups.
Debt to book value of all companies in the market
Black Diamond Therapeutics is an oncology company developing targeted therapies. While in clinical trials, like other biotechs, it relies entirely on equity capital to fund its operations. This graph of total debt clearly demonstrates that Black Diamond's financial model is an exception to the rule and carries risks associated with the need for ongoing capital raising.
P/E of the company, segment and market as a whole
P/E - Black Diamond
Black Diamond Therapeutics is an oncology company developing targeted therapies for cancers caused by specific genetic mutations. This chart reflects investor expectations for its scientific platform. The valuation is not based on current revenue but rather on the future success of its precision-engineered drugs.
P/E of the market segment - Oncology targeted therapy
This industry chart for biotech companies provides key context for Black Diamond. It reflects generally high valuations based on breakthrough hopes. Comparisons with this chart help understand whether Black Diamond's unique platform for developing targeted drugs for cancers caused by specific mutations is considered more promising than its competitors.
P/E of the market as a whole
Black Diamond Therapeutics develops targeted therapies for cancers caused by specific genetic mutations. This is a cutting-edge field in oncology. This chart of overall biotech risk appetite shows whether investors are willing to fund high-tech platforms that can develop multiple drugs but require significant R&D investment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Black Diamond
Black Diamond Therapeutics is an oncology company developing targeted therapies for patients with difficult-to-treat genetic mutations. This graph reflects speculative expectations for its scientific platform. These expectations are contingent on the success of clinical trials and the potential of its drug candidates for specific groups of cancer patients.
%20P%2FE%20Black%20Diamond&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Black-Diamond&v=1772631795937 "Chart of the company's future (projected) P/E Black Diamond")
Future (projected) P/E of the market segment - Oncology targeted therapy
Black Diamond Therapeutics is an oncology company developing targeted therapies for cancers caused by specific genetic mutations. This chart reflects investor expectations for the company's profitability relative to the sector. It allows one to assess the market's confidence in its scientific approach and the potential of its drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-targeted-therapy&v=1772631796057 "Future (projected) P/E graph of the market segment - Oncology targeted therapy")
Future (projected) P/E of the market as a whole
Black Diamond Therapeutics is an oncology company developing targeted therapies for patients with difficult-to-treat genetic mutations. For a clinical-stage biotech like BDTX, this market risk appetite curve is vital. Funding for their cutting-edge, yet risky, research directly depends on investors' willingness to invest in long-term scientific projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772631796100 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Black Diamond
Black Diamond Therapeutics is an oncology company developing targeted therapies for the treatment of cancers caused by specific genetic mutations. This chart shows the company's financial performance at the clinical trial stage, where it operates at the forefront of personalized medicine.
Profit of companies in the market segment - Oncology targeted therapy
Black Diamond Therapeutics develops targeted therapies for cancers caused by specific genetic mutations. This chart shows the profitability of the oncology sector. For BDTX, this reflects the trend toward personalized medicine. Their approach involves identifying "underappreciated" mutations and developing drugs specifically for them.
Overall market profit
Black Diamond Therapeutics is an oncology company developing targeted therapies for patients with genetic mutations that are traditionally difficult to treat. This is a pioneering approach to personalized medicine. The company's success depends on clinical data. General economic cycles, as reflected in this chart, do not affect its scientific activities.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Black Diamond
Black Diamond Therapeutics is an oncology company developing targeted therapies for the treatment of cancers caused by specific genetic mutations. The revenue projections presented here are speculative and reflect expectations based on the success of its MAP platform and the progression of its candidates through clinical trials.
%20profit%20of%20the%20company%20Black%20Diamond&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Black-Diamond&v=1772631796445 "Graph of future (projected) profit of the company Black Diamond")
Future (predicted) profit of companies in the market segment - Oncology targeted therapy
Black Diamond Therapeutics is an oncology company developing targeted therapies for patients with difficult-to-treat genetic mutations. The revenue forecast for this segment depends on the success of their Map platform. This chart reflects the analysts' belief in the future of personalized oncology and the ability to find treatments for niche patient groups.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-targeted-therapy&v=1772631796489 "Graph of future (predicted) profits of companies in a market segment - Oncology targeted therapy")
Future (predicted) profit of the market as a whole
Black Diamond Therapeutics is a clinical-stage oncology company developing targeted therapies for genetically defined cancers. Its future depends on successful research. The market profit forecasts shown here reflect the overall investment climate and risk appetite in the biotech sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772631796542 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Black Diamond
Black Diamond Therapeutics is an oncology company developing targeted therapies for patients with difficult-to-treat genetic mutations. This chart shows a high speculative valuation. Investors are betting on its unique approach to drug discovery and the potential to develop treatments for previously unserved patient groups.
P/S market segment - Oncology targeted therapy
Black Diamond Therapeutics is an oncology company developing targeted therapies for patients with genetically defined cancers previously considered difficult to treat. This chart reflects the average revenue estimate in the biotech sector, providing insight into investor expectations for Black Diamond's scientific platform and clinical development.
P/S of the market as a whole
Black Diamond Therapeutics is an oncology company developing targeted therapies for patients with difficult-to-treat genetic mutations. The company uses a proprietary platform to discover new targets. This chart provides a market-wide perspective on investor sentiment toward high-risk but potentially breakthrough medical technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Black Diamond
Black Diamond Therapeutics is an oncology company developing targeted therapies for patients with genetically specific cancers. This chart shows how the market values the company based on its future revenue potential. It reflects expectations for the success of its targeted approach to cancer treatment.
%20P%2FS%20Black%20Diamond&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Black-Diamond&v=1772631796669 "The graph of the company's future (projected) P/S Black Diamond")
Future (projected) P/S of the market segment - Oncology targeted therapy
Black Diamond Therapeutics is an oncology company developing targeted therapies for the treatment of cancers caused by specific genetic mutations. Its approach is based on precision medicine. This chart reflects investors' confidence in its scientific platform and ability to create effective treatments for specific patient groups.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-targeted-therapy&v=1772631796685 "Future (projected) P/S market segment graph - Oncology targeted therapy")
Future (projected) P/S of the market as a whole
Black Diamond Therapeutics is a biotech company developing targeted therapies for cancers caused by specific genetic mutations. Their success depends on the results of clinical trials. This market optimism chart is important for BDTX. Funding such highly specialized and risky research is only possible with a high investor appetite.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772631796740 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Black Diamond
Black Diamond Therapeutics is a clinical-stage biotechnology company developing precision cancer treatments that target specific genetic mutations. The company currently has no commercial products. This pipeline will reflect its ability to bring the next generation of targeted oncology therapies to market.
Sales of companies in the market segment - Oncology targeted therapy
Black Diamond Therapeutics is an oncology company developing targeted therapies for the treatment of cancers caused by specific genetic mutations. Their approach allows them to create treatments for groups of patients who have not responded to standard therapies. While in clinical trials, the company does not yet have commercial revenue.
Overall market sales
Black Diamond Therapeutics is an oncology company developing targeted therapies for the treatment of cancers caused by specific genetic mutations. Its approach enables the creation of treatments for patient groups who have failed standard therapies. This total revenue chart includes the healthcare sector, where BDTX is at the forefront of personalized oncology.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Black Diamond
Black Diamond Therapeutics develops targeted therapies for the treatment of cancers caused by specific genetic mutations. The company uses its own approach to discover new targets. This chart reflects analysts' confidence in the potential of its scientific platform and its ability to bring drug candidates to commercialization.
%20sales%20of%20the%20company%20Black%20Diamond&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Black-Diamond&v=1772631796908 "Schedule of future (projected) sales of the company Black Diamond")
Future (projected) sales of companies in the market segment - Oncology targeted therapy
Black Diamond Therapeutics is an oncology company developing targeted drugs for the treatment of cancers caused by specific genetic mutations. This chart shows forecasts for the precision oncology market. It reflects the growing trend toward developing "smart" drugs that act only on cancer cells with specific mutations.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-targeted-therapy&v=1772631796936 "Schedule of future (projected) sales of companies in the market segment - Oncology targeted therapy")
Future (projected) sales of the market as a whole
Black Diamond Therapeutics, a company developing targeted cancer therapies, sees this chart as a reflection of investor interest in personalized medicine. The stable economic growth predicted here allows investors to fund breakthrough approaches to cancer treatment based on genetic mutations, which is the core of Black Diamond's work.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772631797001 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Black Diamond
Black Diamond Therapeutics is an oncology company developing targeted therapies. While in clinical trials, it incurs significant R&D expenses. This chart illustrates not current profits, but rather the "cost of innovation"—the amount of investment the company is making in its scientific platform to create the next generation of cancer drugs.
Market segment marginality - Oncology targeted therapy
Black Diamond Therapeutics uses its proprietary platform to develop targeted cancer therapies that target genetic mutations. This graph reflects the potential of its scientific approach. Future high operating income will confirm the success of its developments and its ability to create highly effective drugs.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company Black Diamond
Black Diamond Therapeutics uses its unique platform to discover and develop targeted oncology drugs that target genetic mutations previously considered elusive. This graphic shows a team of scientists searching for "allosteric" mutations to create a new generation of precision cancer therapies.
Share of the company's employees Black Diamond within the market segment - Oncology targeted therapy
Black Diamond Therapeutics is an oncology company developing targeted therapies for patients with genetic mutations previously considered untreatable. Its science-intensive approach requires a team of top scientists in precision medicine. This graph illustrates the concentration of elite scientific talent needed to create breakthrough drugs.
Number of employees in the market segment - Oncology targeted therapy
Black Diamond Therapeutics is an oncology company developing targeted drugs to treat cancers caused by specific genetic mutations. This graphic shows a team of biologists and chemists working at the forefront of personalized medicine, creating "smart" drugs that target only cancer cells with a specific mutation.
Number of employees in the market as a whole
Black Diamond Therapeutics is an oncology company developing targeted therapies for patients with genetically determined cancers. Their research-intensive business requires significant investment. The overall economic situation, reflected in the employment graph, creates a favorable environment for raising capital. Market stability increases investor willingness to invest in long-term biotech projects.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Black Diamond (BDTX)
Black Diamond Therapeutics is an oncology company developing targeted therapies. This chart represents a bet on their scientific platform. Their astronomical market capitalization per employee indicates the market sees enormous potential in their approach to drug development. The company's value is not based on current revenue, but on future blockbusters created by a small team.
%20of%20the%20company%20Black%20Diamond%20(BDTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Black-Diamond-BDTX&v=1772631797269 "Chart of market capitalization per employee (in thousands of dollars) of the company Black Diamond (BDTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Black Diamond Therapeutics is an oncology company developing targeted therapies for patients with genetic mutations. Its market cap is based on the strength of its research platform. This chart shows how investors value its scientific innovation per employee compared to other biotech companies.
%20by%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-targeted-therapy&v=1772631797312 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology targeted therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Black Diamond Therapeutics is an oncology company developing targeted therapies for cancers caused by specific genetic mutations. This metric reflects the potential of its scientific platform and how investors evaluate its ability to create "smart" drugs that target specific cancer drivers.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772631797317 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Black Diamond (BDTX)
Black Diamond is a clinical-stage biotech company developing targeted cancer therapies. They are searching for drugs for specific mutations. This graph is negative. The company consists of scientists engaged in R&D. There is no profit; all funds are spent on development and clinical trials, which, if successful, will generate revenue in the future.
%20Chart%20Black%20Diamond%20(BDTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Black-Diamond-BDTX&v=1772631797333 "Company Profit Per Employee (in thousands of dollars) Chart Black Diamond (BDTX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Black Diamond Therapeutics is an oncology company working on "allosteric" inhibitors. They identify previously unknown mutations and develop targeted drugs to treat them. This chart represents an industry benchmark. For biotech R&D, it serves as a benchmark, demonstrating the potential profitability the sector aspires to achieve if their computational platform and clinical candidates are successful.
%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-targeted-therapy&v=1772631797354 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Black Diamond Therapeutics is a biotech company working on "allosteric" inhibitors. They are searching for drugs for cancers caused by specific mutations that are difficult to attack head-on. This is an R&D platform. The chart shows the R&D investment (negative return) per scientist working on this complex "precision" oncology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772631797397 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Black Diamond (BDTX)
Black Diamond Therapeutics is an oncology company developing targeted therapies for genetically defined cancers. This graph reflects early-stage biotech development. Potentially high revenue per employee in the future will result from the successful commercialization of its innovative drugs targeting specific mutations.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Black-Diamond-BDTX&v=1772631797448 "Sales chart per company employee Black Diamond (BDTX)")
Sales per employee in the market segment - Oncology targeted therapy
Black Diamond (BDTX) is a clinical-stage biotech developing targeted cancer therapies. They use their MAP platform to search for mutations. They have no commercial revenue. This chart reflects their R&D stage: their research staff is focused on research, resulting in zero revenue per employee compared to the industry average.
Sales per employee for the market as a whole
Black Diamond Therapeutics is a biotech company developing smart cancer drugs. Their "MasterKey" platform creates drugs that target entire families of mutations. This is pure R&D. This graph will likely show zero revenue, as their team of scientists is still in clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Black Diamond (BDTX)
Black Diamond (BDTX) is a biotech company developing targeted therapies for cancers caused by specific genetic mutations. This chart shows bearish bets. The high short interest reflects investor skepticism about their scientific platform (MAP) or concerns that their drugs target too narrow a patient population, limiting their market potential.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Black-Diamond-BDTX&v=1772631797523 "Short Shares Chart for the Company Black Diamond (BDTX)")
Shares shorted by market segment - Oncology targeted therapy
Black Diamond (BDTX) is a biotech company developing targeted therapies for cancers caused by specific genetic mutations. This chart illustrates the general skepticism in the precision oncology sector, reflecting investor doubts about the success of clinical trials and the intense competition in this field.
Shares shorted by the overall market
Black Diamond is a clinical-stage oncology company. Its value is tied to the success of its "MAP" drug discovery platform. When market fear (as shown in this chart) mounts, investors flee platform-based, revenue-deficient biotechs. Their path to profitability is long and uncertain, which is unacceptable during risk-off periods.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Black Diamond (BDTX)
Black Diamond (BDTX) is a biotech company specializing in precision oncology. They develop drugs that target specific "allosteric" mutations in cancer cells. This chart measures hype. It shows "overheated" (above 70) due to positive R&D data or "oversold" (below 30) amid delays or setbacks, which is typical for biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Black-Diamond-BDTX&v=1772631797622 "RSI 14 indicator chart for the company's stock Black Diamond (BDTX)")
RSI 14 Market Segment - Oncology targeted therapy
Black Diamond (BDTX) is an oncology company developing next-generation targeted therapies. These target groups of mutations previously considered drug-resistant. This chart measures overall sentiment in the Targeted Oncology sector. It helps distinguish BDTX's development successes from general overheating or overselling in the biotech sector.
RSI 14 for the overall market
Black Diamond (BDTX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BDTX (Black Diamond)
Black Diamond Therapeutics is an oncology company using its MAP platform to develop targeted therapies targeting specific cancer driver mutations. This chart shows the speculative average price target from analysts based on their belief in this scientific R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BDTX-Black-Diamond&v=1772631797727 "A chart showing analyst consensus forecasts for the expected stock price. BDTX (Black Diamond)")
The difference between the consensus estimate and the actual stock price BDTX (Black Diamond)
Black Diamond is a biotech company focused on targeted oncology. Their specialty is identifying previously ignored allosteric mutations to create new classes of drugs. This chart reflects analysts' speculative expectations for their MAP R&D platform and early clinical trial data.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BDTX-Black-Diamond&v=1772631797757 "A chart showing the difference between the consensus forecast and the actual stock price. BDTX (Black Diamond)")
Analyst consensus forecast for stock prices by market segment - Oncology targeted therapy
Black Diamond (BDTX) is a biotech company developing precision cancer drugs. Its "MasterKey" platform targets entire families of mutations, not just a single one. This chart shows the overall expectations for the targeted oncology sector, reflecting whether experts believe in the success of this complex R&D approach.
Analysts' consensus forecast for the overall market share price
Black Diamond Therapeutics is a biotech company specializing in the development of targeted drugs for the treatment of cancer caused by specific genetic mutations. This chart shows the overall risk appetite. For Black Diamond, a clinical-stage company, overall market optimism is critical to attracting the capital needed to fund long-term research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Black Diamond
Black Diamond is a biotech company working in precision oncology. Their platform (MAP) identifies families of mutations in cancer cells and creates drugs that target them all at once. This chart is a pure indicator of faith in their R&D platform. It doesn't reflect revenue, but rather a speculative estimate of their scientific progress and clinical trial data.
AKIMA Market Segment Index - Oncology targeted therapy
Black Diamond Therapeutics uses its MAP platform to discover and develop targeted oncology drugs that target mutations previously considered druggable. This chart shows the average index for the targeted therapy sector. It helps assess how promising Black Diamond's scientific approach is compared to the average.
The AKIM Index for the overall market
Black Diamond Therapeutics is a biotech company developing targeted drugs (MasterKey) for cancers with genetic mutations. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this early-clinical stage research story compares to overall economic trends and risk appetite.
